Table 1.
Demographics, comorbidities and chamber quantifications in patient and healthy subjects.
| Parameter | Patients | Age-matched HS | p-Value |
|---|---|---|---|
| Demographics | |||
| Age (years) | 54.9 ± 8.9 | 48.5 ± 7.2 | 0.05 |
| SBP (mmHg) | 126.9 ± 14.5 | 123 ± 8.4 | 0.50 |
| DBP (mmHg) | 73.8 ± 11.3 | 67.9 ± 6.6 | 0.10 |
| HR (bpm) | 76.1 ± 11 | 69.2 ± 7.6 | 0.06 |
| Body Mass (kg) | 77.2 ± 14.1 | 76.2 ± 13.5 | 0.80 |
| BMI (kg/cm2) | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.90 |
| BSA (m2) | 28.8 ± 6.4 | 28.5 ± 4.8 | 0.90 |
| Comorbidities | |||
| Hypertension | 4 | 0 | 0.03* |
| Hypercholesterolemia | 3 | 0 | 0.07 |
| Diabetes mellitus | 2 | 0 | 0.20 |
| Chemotherapy dose | |||
| Doxorubicin 240 mg/m2 | 11 | 0 | 0.00++ |
| Trastuzumab 8 mg/kg loading + 6 mg/kg | 5 | 0 | 0.01* |
| Radiotherapy | 6 | 0 | 0.00++ |
| Chamber quantifications | |||
| Diameter basal (D) (cm) | 5.2 ± 0.5 | 4.5 ± 0.5 | 0.00++ |
| Diameter mid (D) (cm) | 4.0 ± 0.4 | 3.7 ± 0.4 | 0.10 |
| Diameter apical (D) (cm) | 3.1 ± 0.4 | 2.9 ± 0.3 | 0.20 |
| Diameter basal (S) (cm) | 3.4 ± 0.4 | 2.9 ± 0.3 | 0.00++ |
| Diameter mid (S) (cm) | 2.5 ± 0.3 | 2.4 ± 0.3 | 0.50 |
| Diameter apical (S) (cm) | 1.8 ± 0.3 | 1.6 ± 0.2 | 0.10 |
| EDV full LV (cm3) | 112.6 ± 15.8 | 108.5 ± 14.5 | 0.60 |
| ESV full LV (cm3) | 46.8 ± 10.3 | 41.7 ± 8.4 | 0.30 |
| SV full LV (cm3) | 66.0 ± 12.7 | 66.7 ± 11.9 | 0.90 |
| EF full LV (%) | 58 ± 7 | 62 ± 5 | 0.40 |
| Full LV mass (gm) | 127.6 ± 8.3 | 134.5 ± 9.5 | 0.30 |
Abbreviations: DBP: diastolic blood pressure (BP), SBP: systolic BP, HR: heart rate, BMI: body mass index, BSA: body surface area HS: healthy subjects, D: diastolic, S: systolic, EDV: end diastolic volume, ESV: end systolic volume, SV: stroke volume, EF: ejection fraction.
*
Significant differences between patients and healthy subjects.
++
p < 0.01.